Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Non-Current Assets (2019 - 2025)

Fennec Pharmaceuticals' Non-Current Assets history spans 7 years, with the latest figure at $3.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets rose 326.76% year-over-year to $3.5 million, compared with a TTM value of $3.5 million through Dec 2025, up 326.76%, and an annual FY2025 reading of $3.5 million, up 326.76% over the prior year.
  • Non-Current Assets for Q4 2025 was $3.5 million at Fennec Pharmaceuticals, up from $3.2 million in the prior quarter.
  • The five-year high for Non-Current Assets was $4.1 million in Q2 2025, with the low at $6000.0 in Q4 2023.
  • Average Non-Current Assets over 5 years is $1.1 million, with a median of $237500.0 recorded in 2022.
  • Year-over-year, Non-Current Assets plummeted 97.16% in 2023 and then surged 13600.0% in 2024.
  • Tracing FENC's Non-Current Assets over 5 years: stood at $35000.0 in 2021, then soared by 502.86% to $211000.0 in 2022, then plummeted by 97.16% to $6000.0 in 2023, then surged by 13600.0% to $822000.0 in 2024, then skyrocketed by 326.76% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Non-Current Assets are $3.5 million (Q4 2025), $3.2 million (Q3 2025), and $4.1 million (Q2 2025).